Eckert & Ziegler Strahlen- und Medizintechnik AG

Earnings Release • Mar 30, 2023

News Details

Corporate | 30 March 2023 07:45

​​​​​Eckert & Ziegler: Successful fiscal year 2022

EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Annual Results/Forecast

​​​​​Eckert & Ziegler: Successful fiscal year 2022

30.03.2023 / 07:45 CET/CEST

The issuer is solely responsible for the content of this announcement.

Berlin, 30 March 2023 – Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) achieved sales of € 222.3 million in FY 2022. Compared to the previous year, sales increased by € 41.9 million or 23%. Net income reached € 29.3 million, thus increasing by nearly 20% compared to the previous year’s figure adjusted for special effects.

In the Isotope Products segment , sales rose by 37% to € 131.4 million. The reason for the increase is the acquisition of the Argentinian Tecnonuclear S.A. in 2022 and a strong Asian business.

In the Medical segment , revenue grew by 8% to € 90.9 million. The largest growth driver continues to be the business with radiopharmaceuticals, which showed growth of 37% to

€ 66.4 million across all segments.

Cash and cash equivalents as of 31 December 2022 decreased to € 82.7 million; less loan liabilities, net liquidity amounted to € 60.3 million. Compared to the end of 2021, this corresponds to a decrease of € 27.6 million.

For the 2023 financial year, the Executive Board expects to achieve revenues of nearly € 230 million in the operating segments – Medical and Isotopes Products – and, as in 2022, a net profit of € 31 million. No revenues are expected in the Other segment. However, higher expenses for non-capitalizable clinical developments will occur in this segment in 2023, which will increase the loss in the Other segment by € 4 million to € 6 million. The consolidated net income (net profit) as the total of all segments will then amount to around € 25 million in 2023.

The forecast is based on a weighted average exchange rate of USD 1.05 per euro and the assumption that Eckert & Ziegler will not be affected by any major disruptions from the war in Ukraine.

The Executive Board and Supervisory Board will propose a dividend of € 0.50 per dividend-bearing share (previous year € 0.50) at the Annual General Meeting.

The full 2022 financial statements can be found here:

https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz22e.pdf

About Eckert & Ziegler.

Eckert & Ziegler Strahlen- und Medizintechnik AG with nearly 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.

Contributing to saving lives.

For enquiries please contact:

Eckert & Ziegler AG, Karolin Riehle, Investor Relations

Robert-Rössle-Str. 10, 13125 Berlin, Germany

Tel.: +49 (0) 30 / 94 10 84-138

karolin.riehle@ezag.de , www.ezag.com

---

30.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com

---

Language:	English
Company:	Eckert & Ziegler Strahlen- und Medizintechnik AG
	Robert-Rössle-Str.10
	13125 Berlin
	Germany
Phone:	+49 30 941084-138
Fax:	+49 30 941084-112
E-mail:	karolin.riehle@ezag.de
Internet:	www.ezag.de
ISIN:	DE0005659700
WKN:	565970
Indices:	SDAX, TecDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1594623

End of News	EQS News Service